Myriad Genetics(MYGN) 2023 Earnings Summary
Bullish Points:
1. As of June 30, 2023, the company had cash, cash equivalents, and marketable securities of $127.8 million.
2. Cash used in operating activities decreased by $62.1 million for the six months ended June 30, 2023, compared to the same period in the prior year.
3. The company has authorization to repurchase up to $200.0 million of its outstanding common stock, with $110.7 million still available as of June 30, 2023.
Bearish Points:
1. Other expense increased by $1.9 million for the six months ended June 30, 2023, primarily due to a $1.7 million loss from foreign currency fluctuations and a $1.4 million loss on investment securities.
2. Income tax expense for the six months ended June 30, 2023 was $2.1 million, with an effective tax rate of (1.2)%.
3. The company is exposed to interest rate risk through borrowings under the ABL Facility and foreign currency exchange risks, primarily in Japanese yen.
4. Inflation may impact labor costs, costs to generate sales and produce testing results, and costs of lab supplies, potentially affecting the company's profitability and ability to obtain additional funding.
5. The company is subject to a securities class action lawsuit and stockholder derivative actions, which could adversely impact its business, cash position, results of operations, or financial condition.
6. The company agreed to pay a settlement amount of $77.5 million for the securities class action lawsuit, consisting of at least $20.0 million in cash and up to $57.5 million in freely tradeable shares of common stock.
7. The company paid $14.0 million to settle a lawsuit related to alleged negligence, breach of contract, and associated torts in connection with an alleged error in testing performed in 2004.
8. No stock repurchases were made during the six months ended June 30, 2023.
9. The company does not intend to pay dividends on its common stock for the foreseeable future, retaining any future earnings for business development, operation, and expansion.
10. The terms of the company's ABL Facility restrict its ability to pay dividends.
For more information, you can read the original text of Myriad Genetics(MYGN)'s financial report: https://www.sec.gov/Archives/edgar/data/899923/000089992323000058/mygn-20230630.htm
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
